Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

BioNexus Gene Lab (BGLC) Invested Capital (2018 - 2025)

BioNexus Gene Lab's Invested Capital history spans 8 years, with the latest figure at $6.8 million for Q3 2025.

  • For Q3 2025, Invested Capital fell 27.4% year-over-year to $6.8 million; the TTM value through Sep 2025 reached $6.8 million, down 27.4%, while the annual FY2024 figure was $8.3 million, 13.82% down from the prior year.
  • Invested Capital for Q3 2025 was $6.8 million at BioNexus Gene Lab, down from $7.5 million in the prior quarter.
  • Across five years, Invested Capital topped out at $9.7 million in Q4 2023 and bottomed at $5.6 million in Q2 2023.
  • The 5-year median for Invested Capital is $7.2 million (2022), against an average of $7.6 million.
  • The largest annual shift saw Invested Capital soared 70.7% in 2024 before it dropped 27.4% in 2025.
  • A 5-year view of Invested Capital shows it stood at $7.2 million in 2021, then fell by 7.61% to $6.7 million in 2022, then skyrocketed by 44.9% to $9.7 million in 2023, then fell by 13.82% to $8.3 million in 2024, then fell by 18.1% to $6.8 million in 2025.
  • Per Business Quant, the three most recent readings for BGLC's Invested Capital are $6.8 million (Q3 2025), $7.5 million (Q2 2025), and $7.8 million (Q1 2025).